Tough Decision Making in Pembrolizumab-Associated Acute Interstitial Nephritis: A Case Report

Tough Decision Making in Pembrolizumab-Associated Acute Interstitial Nephritis: A Case Report

Pembrolizumab is an immune checkpoint inhibitor used as a cancer therapy. The incidence of immune related adverse events in patients receiving immune checkpoint inhibitors can be as high as 59%–85%. Renal adverse effects are uncommon, but the incidence of kidney toxicity related to pembrolizumab i...

Full description

Bibliographic Details
Main Authors: João Grilo, Joana Coutinho, Mário Góis, Catarina Reis Santos, Rui Alves Filipe, Ernesto Rocha
Format: Article
Language:English
Published: Publicações Ciência e Vida 2023-06-01
Series:Revista Portuguesa de Nefrologia e Hipertensão
Subjects:
immune checkpoint inhibitors/adverse effects
neoplasms/drug therapy
nephritis
nterstitial/chemically induced
pembrolizumab/adverse effects
Online Access:https://spnefro.pt/_doi/1a04465e-62e7-4027-a6ec-4aa67429960e/73d93e4e-d3ab-42db-980d-708f20b0353f

Internet

https://spnefro.pt/_doi/1a04465e-62e7-4027-a6ec-4aa67429960e/73d93e4e-d3ab-42db-980d-708f20b0353f

Similar Items